AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32109991
Drug: Loose Combination
RxNorm normalized name: loose wheat smut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loose Combination (LC) of amlodipine/losartan and rosuvastatin
Trial: 32486256
Drug: DHA-rich fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich fish oil capsules (2 g per day, 860 mg DHA + 120 mg EPA)
Trial: 32658503
Drug: Active Neurofeedback
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Neurofeedback Training (NFT), 24 sessions, twice a week
Trial: 36529811
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus topical corticosteroids
Trial: 36384746
Drug: Angiotensin receptor
RxNorm normalized name: Angiotensin receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin receptor blockers (telmisartan 40 mg/day)
Trial: 34664527
Drug: CoQ10 100
RxNorm normalized name: Walgreens CoQ10 100mg Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ10 100 mg/day for 12 weeks
Trial: 34950221
Drug: Xiaoyutang combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xiaoyutang combined with intraperitoneal heat perfusion chemotherapy
Trial: 34950221
Drug: Intraperitoneal thermal
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraperitoneal thermal perfusion chemotherapy (Control)
Trial: 38956594
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg psilocybin
Trial: 34701532
Drug: GC4711 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC4711 (100 mg IV prior to each of 5 consecutive daily SBRT fractions of 10-12Gy)
Trial: 34701532
Drug: Placebo (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (in the Phase 2 cohort concurrent with SBRT)
Trial: 35766657
Drug: Atazanavir, Daclatasvir,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir, Daclatasvir, or Sofosbuvir (in combination)
Trial: 32833476
Drug: Adherence to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherence to cancer control behaviors and treatment compliance
Trial: 33432635
Drug: Medication Overuse
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medication Overuse Treatment Strategy trial
Trial: 33432635
Drug: Migraine preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Migraine preventive medication
Trial: 35951066
Drug: Reiki therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reiki therapy (21 sessions)
Trial: 32348605
Drug: Intra-articular methylprednisolone
RxNorm normalized name: methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-articular methylprednisolone acetate (MPA) 100 mg/joint
Trial: 32348605
Drug: Intramuscular methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular methylprednisolone acetate (MPA) 200 mg
Trial: 36278451
Drug: Recovery-focused therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recovery-focused therapy plus treatment as usual
Trial: 32101269
Drug: ICG group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICG group (laparoscopic gastrectomy using near‐infrared imaging after endoscopic peritumoral injection of ICG 1 day before surgery)
Trial: 36891906
Drug: Antithrombotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antithrombotic therapy
Trial: 34143234
Drug: Inhalation anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation anesthesia (IAA) with sevoflurane treatment
Trial: 34143234
Drug: Intravenous anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous anesthesia (IVA) with propofol treatment
Trial: 33284679
Drug: Hydroxychloroquine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (400 mg/d for 3 days followed by 200 mg/d for 11 days)
Trial: 33284679
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid (500 mg/d followed by 250 mg/d) as a placebo‐equivalent control
Trial: 32498269
Drug: Porphyra tenera
RxNorm normalized name: Porphyra tenera extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porphyra tenera extract (PTE) 2.5 g/day for 8 weeks
Trial: 32498269
Drug: Placebo (crystal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (crystal cellulose capsules) for 8 weeks
Trial: 32498269
Drug: Porphyra tenera
RxNorm normalized name: Porphyra tenera extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porphyra tenera extract (PTE) 2.5 g/day for 8 weeks (subgroup analysis of 101 subjects without URI)
Trial: 37573352
Drug: In-centre nocturnal
RxNorm normalized name: Nocdurna
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In-centre nocturnal haemodialysis (INHD), 6 to 8 hours thrice-weekly for 6 months
Trial: 37573352
Drug: Conventional haemodialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional haemodialysis (thrice-weekly daytime in-centre haemodialysis, 3.5–5 hours per session)
Trial: 34407342
Drug: Adjuvant pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant pembrolizumab (200 mg intravenously once every 3 weeks for up to 17 cycles)
Trial: 32427795
Drug: Health Empowerment
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Health Empowerment Intervention (HEI) consisting of 6 weekly sessions based on the Health Empowerment Theory
Trial: 32319791
Drug: Conventional Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Therapy
Trial: 33862045
Drug: HIC (Hepatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIC (Hepatic Insulin Clearance)
Trial: 33156995
Drug: Reference product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product (metronidazole cream)
Trial: 33156995
Drug: 0.56% MTZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.56% MTZ cream (negative control)
Trial: 33156995
Drug: 0.95% MTZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.95% MTZ cream (negative control)
Trial: 33156995
Drug: 0.75% MTZ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75% MTZ cream
Trial: 32311911
Drug: 400 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 μg of the β2‐agonist salbutamol
Trial: 32648391
Drug: Herb-separated moxibustion
RxNorm normalized name: serrated swimming crab, cooked preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herb-separated moxibustion at Jinsuo (GV 8)-eight-diagram points, applied for 40 min once daily for 8 weeks.
Trial: 32648391
Drug: Pinaverium bromide
RxNorm normalized name: pinaverium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pinaverium bromide tablets, 50 mg three times a day for 8 weeks.
Trial: 32648391
Drug: Tongxieyaofang decoction,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tongxieyaofang decoction, one dose a day for 8 weeks, taken separately in two times.
Trial: 34666302
Drug: Pentoxifylline (PTX)
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline (PTX) 400 mg three times a day for 10 days
Trial: 33600687
Drug: Inhaled Human
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Human Insulin (Exubera®)
Trial: 33600687
Drug: Subcutaneous Insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous Insulin
Trial: 33753352
Drug: High-dose 24-hour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose 24-hour infusion of tranexamic acid
Trial: 33536398
Drug: Pemafibrate 0.025-0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemafibrate 0.025-0.2 mg BID
Trial: 34665865
Drug: LD-RTX monotherapy
RxNorm normalized name: LD norgestrel
DrugBank: Norgestrel (DB09389)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LD-RTX monotherapy
Trial: 36333954
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic Acid (5-mg intravenously)
Trial: 35978361
Drug: Fascia iliaca
RxNorm normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascia iliaca compartment block (FICB) administered by paramedics
Trial: 33499025
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g β-Lactoglobulin (BLG)
Trial: 33499025
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g Whey Protein Isolate (WPI)
Trial: 34105063
Drug: Intramuscular paromomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular paromomycin monotherapy (20 mg/kg for 21 days) in African patients
Trial: 34105063
Drug: Intramuscular paromomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular paromomycin monotherapy (15 mg/kg for 21 days) in Indian patients
Trial: 34105063
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (15 mg/kg for 17 days with sodium stibogluconate) in African patients
Trial: 35947046
Drug: Oxytocin receptor
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin receptor antagonists
Trial: 33947690
Drug: Veliparib throughout
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib throughout (240 mg BID for 14 days, then 400 mg BID maintenance)
Trial: 33947690
Drug: Veliparib combination
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib combination only (240 mg BID for 14 days, then placebo)
Trial: 33947690
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo plus chemotherapy followed by placebo)
Trial: 33947690
Drug: Veliparib combination
RxNorm normalized name: veliparib
DrugBank: Veliparib (DB07232)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Veliparib combination only
Trial: 36524387
Drug: Cognitive Orientation
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Orientation to daily Occupational Performance (CO-OP) Approach
Trial: 35027302
Drug: Aromatherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatherapy with inhaled lavender essential oil (n = 30)
Trial: 32584996
Drug: Alendronate after
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate after stopping treatment
Trial: 32314290
Drug: Zataria multiflora
RxNorm normalized name: Reynoutria multiflora root oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zataria multiflora extract 10 mg/kg/day (Z10)
Trial: 32314290
Drug: Zataria multiflora
RxNorm normalized name: Reynoutria multiflora root oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zataria multiflora extract 5 mg/kg/day (Z5)
Trial: 36474755
Drug: EP-104IAR (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP-104IAR (15 mg)
Trial: 35120193
Drug: Antioxidants (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidants (3 g IV vitamin C and 100 mg/kg N‐acetylcysteine)
Trial: 32406210
Drug: Electroconvulsive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive therapy (ECT), 8.3 ± 2 sessions
Trial: 32412700
Drug: Esketamine 84
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Esketamine 84 mg nasal spray twice-weekly for 4 weeks + standard-of-care treatment
Trial: 32412700
Drug: Placebo nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray twice-weekly for 4 weeks + standard-of-care treatment
Trial: 35085482
Drug: Rectal indometacin
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal indometacin (100 mg) administered 30 min before ESWL
Trial: 35085482
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical glycerin suppositories) administered 30 min before ESWL
Trial: 35085482
Drug: Rectal indometacin
RxNorm normalized name: indomethacin Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal indometacin (100 mg)
Trial: 35085482
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical glycerin suppositories)
Trial: 37769545
Drug: Controlled-release carbamazepine
RxNorm normalized name: carbamazepine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release carbamazepine (CBZ-CR)
Trial: 32381496
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal cannula (HFNC) at 3 L·kg‐1·min‐1
Trial: 32381496
Drug: Standard oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oxygen therapy (Control)
Trial: 32785213
Drug: 10 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µg BNT162b1
Trial: 32785213
Drug: 30 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 µg BNT162b1
Trial: 35092241
Drug: Multidisciplinary approach
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary approach to treatment
Trial: 35092241
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy regimen
Trial: 34813489
Drug: Videoconference-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Videoconference-based cognitive behavioral therapy (vCBT)
Trial: 33051240
Drug: Autologous dendritic
RxNorm normalized name: COVID19 s-vax loaded autologous dendritic cell vaccine
DrugBank: COVID19 s-vax loaded autologous dendritic cell vaccine (DB15814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous dendritic cell (DC) vaccines
Trial: 33051240
Drug: Extracellular/soluble ICOSL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extracellular/soluble ICOSL released from vaccine DCs
Trial: 35756871
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with atorvastatin calcium tablets (20 mg/d for 15 days), traditional Chinese medicine (TCM) decoctions, and acupuncture therapy once daily for 15 days.
Trial: 35756871
Drug: Atorvastatin calcium
RxNorm normalized name: Atorvastatin Calcium
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin calcium tablets (20 mg/d for 15 days)
Trial: 32674250
Drug: 80 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 g/d oatmeal
Trial: 32674250
Drug: 80 g/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 g/d refined white rice
Trial: 33991868
Drug: Mobile application
RxNorm normalized name: Mahana IBS CBT Mobile Application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobile application for treatment adherence and symptom management
Trial: 36008246
Drug: Standard conservative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard conservative treatments
Trial: 34174551
Drug: High nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High nicotine (0.5 mg) with low menthol (0.5%)
Trial: 34174551
Drug: Low nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low nicotine (0.25 mg) with low menthol (0.5%)
Trial: 34174551
Drug: Saline control
RxNorm normalized name: GLYCERIN 0.53 g in 1 mL CUTANEOUS INJECTION [Glycerol-Saline Control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline control (0.0 mg) with low menthol (0.5%)
Trial: 34174551
Drug: High nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High nicotine (0.5 mg) with saline control (0.0%)
Trial: 34174551
Drug: Low nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low nicotine (0.25 mg) with saline control (0.0%)
Trial: 35320813
Drug: Traditional swallowing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional swallowing rehabilitation treatment
Trial: 32224489
Drug: Affect-focused internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Affect-focused internet-based psychodynamic therapy (IPDT) for 8 weeks
Trial: 34582037
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of ropivacaine 0.2% at 6 ml/h
Trial: 34582037
Drug: Programmed, intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed, intermittent boluses of ropivacaine 0.2% at 10 ml every 8th hour
Trial: 34174225
Drug: Exoskeleton-Assisted Anthropomorphic
RxNorm normalized name: Corallium rubrum exoskeleton preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exoskeleton-Assisted Anthropomorphic Movement Training (EAMT) therapy
Trial: 34174225
Drug: Conventional upper
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional upper limb therapy
Trial: 33597056
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g milk protein (MILK)
Trial: 36170964
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g plant-derived protein blend (PLANT-BLEND) combining 15 g wheat, 7.5 g corn, and 7.5 g pea protein
Trial: 32557601
Drug: Ribociclib 400
RxNorm normalized name: ribociclib 400 MG / letrozole 2.5 MG Daily Dose Carton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribociclib 400 mg single-dose
Trial: 32557601
Drug: Multiple 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple 400 mg ribociclib doses
Trial: 32557601
Drug: Multiple 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple 600 mg ribociclib doses
Trial: 32557601
Drug: Ritonavir with
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ritonavir with ribociclib 600 mg multiple doses
Trial: 33783964
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (Lantus; IGlar)
Trial: 35751029
Drug: Remifentanil (Ce
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (Ce of 4.0 ng.ml−1 during TCI of 3.5 μg.ml−1 propofol) in PD patients
Trial: 35751029
Drug: Remifentanil (Ce
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil (Ce of 4.0 ng.ml−1 during TCI of 3.5 μg.ml−1 propofol) in NPD patients
Trial: 34120613
Drug: Daily intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily intake of alcohol
Trial: 34411872
Drug: Rational Emotive
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rational Emotive Behavior Therapy (REBT), 8-week group-based counseling sessions
Trial: 39028360
Drug: Closed-loop insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop insulin delivery
Trial: 33532993
Drug: PIEB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIEB with 2.5 mL of bupivacaine 0.25% plus fentanyl 8 µg·mL‐1 at 30 min interval
Trial: 33532993
Drug: PIEB with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PIEB with 2.5 mL of bupivacaine 0.25% plus fentanyl 8 µg·mL‐1 at more than 30 min interval
Trial: 35351058
Drug: Patient empowerment
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient empowerment project for training of bladder preparation
Trial: 35351058
Drug: Pilot trial
RxNorm normalized name: Picot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilot trial investigating safety of PSMA-PET for focal dose escalation RT
Trial: 35351058
Drug: Urethral sparing
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urethral sparing in focal dose escalation
Trial: 35089999
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea containing 550 mg mulberry leaf extract (MLE), 3 times a day for 4 weeks
Trial: 32854125
Drug: Immediate operative
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Immediate operative therapy
Trial: 35098659
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids or low-dose antipsychotic medication (fast-fail option)
Trial: 33019891
Drug: Cholecalciferol 1000-2000
RxNorm normalized name: cholecalciferol 2000 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 1000-2000 IU daily or 50000 IU weekly until vitamin D levels >20 ng/mL (group IIa) or >30 ng/mL (group IIb)